Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
Nanexa AB announced a global exclusive license and collaboration agreement with Novo Nordisk for the use of its proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform. This partnership will focus on therapeutic peptide drugs aimed at treating obesity, type 2 diabetes, and other cardiometabolic diseases.
The agreement includes up to five development programs and plans for long-acting injectable formulations with different administration-frequency profiles, specifically targeting monthly and quarterly administration.
Novo will lead the global development and commercialization efforts under the agreement. Nanexa is set to receive total payments of up to EUR 1.165 billion, which includes EUR 615 million in upfront payment and additional milestone payments. Furthermore, low single-digit royalties on global net sales of the developed products are also part of the agreement.
David Westberg, CEO of Nanexa, expressed enthusiasm about the collaboration, stating that it underscores the validation of the PharmaShell® platform and positions the company to expand into additional therapeutic areas. He emphasized the aim to develop products with less frequent dosing for chronic conditions.
Göran Ando, Chairman of Nanexa, remarked that this agreement signifies a new phase of financial growth for the company, enabling broader applications of their ALD technology across various therapeutic areas. He mentioned the importance of maintaining a successful partnership with Novo while exploring new project developments.